Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?

Sacubitril/Valsartan (LCZ696) reduced sudden cardiac death in the PARADIGM-HF trial. However, the mechanism by which LCZ696 reduces ventricular arrhythmias remains unclear. The aim of this study was to compare electrocardiographic (ECG) parameters and mechanical dispersion index, assessed by left ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentim Gonçalves, António, Pereira-da-Silva, Tiago, Galrinho, Ana, Rio, Pedro, Moura Branco, Luísa, Soares, Rui, Feliciano, Joana, Ilhão Moreira, Rita, Cruz Ferreira, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616876/
https://www.ncbi.nlm.nih.gov/pubmed/31216679
http://dx.doi.org/10.3390/jcm8060869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616876/
https://www.ncbi.nlm.nih.gov/pubmed/31216679
http://dx.doi.org/10.3390/jcm8060869

Ejemplares similares